-umab
bococizumab
lucatumumab
patritumab
agonistic monoclonal antibody
antigenomic
intrabody
alloantibody
reagin
cibisatamab
teplizumab
dorlixizumab
antiantibody
siltuximab
sulesomab
panitumumab
chromobody
conatumumab
biciromab
immunonaive
robatumumab
zolimomab
presentation
olendalizumab
drozitumab
monoclonal
-a-
-ab
pancytokeratin
onartuzumab
iratumumab
idiospecific
heterophil antibody
properdin
Forssman antibody
oleclumab
heterophile antibody
polyantibody
polyvalent
dacetuzumab
complement
bezlotoxumab
antiustekinumab
-i-
brentuximab
sifalimumab
immunoprobe
Ab
lenzilumab
polytypic